J&J expects up to $3.5 billion in COVID vaccine sales this year

This post was originally published on this site

https://i-invdn-com.investing.com/trkd-images/LYNXMPEI0O0G6_L.jpg

The single-dose J&J (NYSE:JNJ) shot, once touted as an important tool for vaccinating people living in hard-to-reach areas, has been behind its schedule for deliveries in the United States and Europe.

The drugmaker last year faced quality problems at a Baltimore manufacturing facility, resulting in wastage of millions of doses.

The forecast comes at a time when the company looks to separate its consumer health unit and focus on its medical devices and pharmaceuticals businesses.